European start-ups Akribion, Aplagon each draw funding: Venture Report

While the week’s biggest funding was a $112 million round for Australian radiopharma company Advancell Pty. Ltd., two smaller companies in Europe also attracted VCs’ cash.

Akribion Therapeutics GmbH emerged from stealth mode on Tuesday, revealing its intentions to develop nuclease-based therapies that deplete specific cell types based on a given RNA sequence. The Zwingenberg, Germany-based start-up will first attempt to deploy its programmable cell depletion technology to treat HPV-associated oropharyngeal head and neck cancer, but eventually may stretch beyond oncology to explore the platform’s use in immunology, fibrosis and infectious diseases...